Search
>
News_Details

Biopharmaceuticals have risen against the market, becoming a “golden stone” in the industry

Author:
Source:
2018/09/28 15:39
Page view
In 2014, affected by the medical reform policy, most domestic pharmaceutical companies are still filled with the shadow of “price reduction”, and profits are shrinking, and it is urgent to find new profit points. However, biopharmaceuticals have basically entered the "National Essential Drugs List" as anti-cancer drugs, and the impact has been minimal, and many products have even obtained the authorization of "autonomous pricing."
 
In 2014, affected by the medical reform policy, most domestic pharmaceutical companies are still filled with the shadow of “price reduction”, and profits are shrinking, and it is urgent to find new profit points. However, biopharmaceuticals have basically entered the "National Essential Drugs List" as anti-cancer drugs, and the impact has been minimal, and many products have even obtained the authorization of "autonomous pricing." At present, in the entire medical field, biopharmaceuticals can be described as unique, and its broad market prospects have been favored by many investment institutions, and it has become a “golden stone” in the industry.
 
The prospect of biopharmaceuticals is generally optimistic, and the VC industry is constantly moving.
 
On May 13, 2014, the mobile phone industry giant "Sams" announced that it will invest 2 billion US dollars in the biopharmaceutical industry in the short term, mainly into biosimilars and drugs not protected by intellectual property rights.
 
On July 6, 2014, Qin Yufeng, general manager of Shandong Dong'e Ejiao Group, said: “Biopharmaceuticals will become a new growth point for the company. In addition to the two biopharmaceutical varieties Ruitongli and Baijieyi, which are already in production, there are still two companies. a reserve of biopharmaceutical varieties."
 
On July 19, 2014, Jiangsu Huahengchang Group and Jilin Biological Research Institute reached a merger agreement, which will vigorously promote the national marketization process of the new reagent for cancer detection “Pre-check No.1”.
 
On August 14, Zhongheng Group announced that it plans to invest in two Israeli pharmaceutical companies for US$11 million.
 
............
 
Whether it is the domestic market or the foreign market, many powerful investment institutions are gradually targeting the bio-pharmaceutical industry, and continue to make great efforts or mergers or acquisitions, and strive to win a new round of investment opportunities, losing the future profitability of large enterprises.
 
In this regard, the authority of the VC industry pointed out that China's biopharmaceutical industry has huge market opportunities: 1. Some brand biopharmaceuticals are gradually separated from the period of intellectual property patent protection, and biopharmaceutical generic drugs are increasing in the future; 2. Biopharmaceuticals are very strong. Reproducibility, high threshold; 3, most of the domestic bio-pharmaceutical products are not included in medical insurance, enterprises are easy to obtain independent pricing, profit margins are more extensive. The biopharmaceutical industry is generally optimistic, and a strong company will naturally not let go of this fat.
 
The incidence of cancer is increasing year by year, and tumor resistance testing products lead biopharmaceuticals.
 
The Global Cancer Report - 2014 shows that in 2012, half of the world's new cancer cases appeared in Asia, and China topped the list. The annual death toll of 2.2 million people is 26.8% of the world's total. The result is shocking. In China, people "talk about cancer discoloration", and conventional cancer detection and prevention treatment is expensive and difficult to get popular. In foreign countries, the detection and prevention of cancer has been vigorously promoted by the government and many third-party institutions, and the effect is quite satisfactory. However, it is undeniable that due to the difficult characteristics of early detection of tumors, there is still no way for cancer in the middle and late stage at home and abroad, and only through various means to prolong the life of patients.
 
In view of this, the biopharmaceutical industry at home and abroad has increased research on cancer detection, prevention, and treatment, and once it has made major breakthroughs in the field, it often attracts very strong market returns, and it is also the focus of many VCs. field. Recently, investors have been eager to take Neptunus, because the company's new drug anti-tumor "Tigero film" successfully obtained government approval. Similarly, the “pre-test No. 1” cancer detection reagent mentioned above was acquired by the Huahengchang Group because it obtained the intellectual property patent certificate and became the “enterprise independent pricing product” of the National Development and Reform Commission.
 
Observers believe that the high-tech industry investment scale is large, but the return income is often more abundant, bio-pharmaceutical as the pillar of the entire industry, its return rate is the top industry. Under the guidance of the trend of the whole society to pay attention to health and advocate green living, it is only natural that it will be taken seriously by the investment community.